中国围绝经期妇女体脂含量与骨密度关系的初步研究

目的探讨肌肉、脂肪含量与围绝经期骨质疏松妇女骨密度之间的关系。方法利用双能X线骨密度测量仪(美国,Hologic DiscoveryA型)测量门诊围绝经期妇女(90例,年龄:45~52岁(47.3±8.2))骨密度与体脂含量;同时测量登记受试者的年龄、身高、体重。结果结果显示,21%受试者腰椎和股骨骨量降低,全身脂肪含量(20675.129±5080.44)g与腰椎骨密度(0.91±0.177)g/cm2(P>0.05,r=-0.17)和髋部骨密度(0.99±0.102)g/cm2(P>0.05,r=0.158)没有相关性,肌肉含量(39790.80±6551.54)g与腰椎骨密度没有相关性(P>0.05,r=0.078),但是与髋部骨密度高度正相关(P<0.05,r=0.216)。体重(63.01±9.39)kg和腰椎(P<0.05,r=0.217)和髋部(P<0.05,r=0.305)骨密度高度正相关;BMI指数(24.6751±3.45637)与腰椎(P<0.05,r=0.244)和髋部(P<0.01,r=0.339)骨密度高度正相关。结论研究结果表明BMI指数和肌肉含量与围绝经期妇女髋部骨密度高度相关。     

甘肃省兰州地区中老年女性骨密度现状调查及危险因素分析

目的调查研究甘肃省兰州地区中老年女性的骨密度情况,并分析体重指数与骨质疏松的相关性。方法选取2019年5月1日至2019年10月30日期间于甘肃省妇幼保健院行健康体检的女性。详细记录其年龄、绝经状态、身高及体重,采用双能X线吸收骨密度仪进行检测。结果共纳入2 078名研究对象。其中绝经前组204名,占9.82%,平均年龄(41.10±3.19)岁;围绝经期组443名,占21.32%,平均年龄(49.29±2.18)岁;绝经后组1 431名,占68.86%,平均年龄(56.25±7.59)岁。围绝经期组及绝经后组平均绝经年龄分别为(50.43±1.30)岁、(48.42±3.06)岁。三组平均身高、体重及体重指数分别为(1.59±0.05) m、(59.58±7.78) kg及(23.71±3.11) kg/m2。左侧股骨颈的平均骨密度分别为:绝经前组(0.85±0.14) g/cm2、围绝经期组(0.91±0.15) g/cm2、绝经后组(0.82±0.12) g/cm2;左侧全部髋关节的平均骨密度分别为:绝经前组(0.99±0.16)g/cm2、围绝经期组(0.97±0.17) g/cm2、绝经后组(0.88±0.13) g/cm2。腰1～4全部椎体的平均骨密度分别为:绝经前组(1.13±0.22) g/cm2、围绝经期组(1.10±0.20) g/cm2、绝经后组(0.97±0.15) g/cm2。所有绝经前女性的骨密度均正常;围绝经期女性中,正常骨密度占45.15%,骨量减少占32.28%,骨质疏松占22.57%;绝经后女性中,正常骨密度占19.57%,骨量减少占33.54%,骨质疏松占46.89%。Spearman等级相关分析结果示BMI与骨质疏松的发病率呈正向显著相关。结论甘肃省兰州地区中老年女性的骨质疏松发病率随年龄的增长而明显增高,尤其是绝经后及肥胖者,定期监测骨密度成为其不可或缺的体检项目。     

IL-33与绝经后骨质疏松女性骨密度和骨代谢指标相关性研究

目的 探索血清白细胞介素-33(IL-33)与绝经后骨质疏松女性骨密度和骨代谢指标相关性。方法 采用酶联免疫吸附法测定50例绝经后骨质疏松患者和50例正常绝经后妇女血清IL-33水平。采用双能X线骨密度仪(DXA)测量患者和对照组的骨密度(BMD)。检测维生素D、钙、碱性磷酸酶(ALP)、甲状旁腺激素(PTH)水平,以及1型胶原C末端肽(CTX)和1型前胶原N端前肽(P1NP)等骨转换指标。结果 在绝经后骨质疏松症女性中,IL-33水平显著低于健康对照组[(3.53±2.45) pg/mL vs (13.72±5.39) pg/mL,P=0.007];Spearman相关分析表明血清IL-33水平与年龄、BMI、PTH、CTX和P1NP水平呈负相关,与腰椎BMD和股骨颈BMD呈正相关。多元回归分析表明,年龄、BMI、腰椎BMD、PTH、股骨颈BMD和血清CTX和P1NP水平是骨质疏松症患者血清IL-33水平降低的独立预测因子。结论 血清IL-33降低是绝经后骨质疏松患者股骨颈和腰椎骨密度降低和骨转换增速的危险因素。     

新疆乌鲁木齐地区绝经后妇女骨密度情况的调查

目的探讨该地区绝经期妇女随绝经年限延长,腰椎及股骨近端骨密度减低情况,及绝经对骨密度的影响。方法应用法国DMS公司生产的CHALLENGER双能X线骨密度仪测定正位腰椎(L2-4)及股骨近端(NECK区、Troch区)BMD。结果各组腰椎(L2-4)BMD低于股骨近端(NECK区、Troch区)的BMD,并且配对t检验显示腰椎BMD与股骨颈及股骨大转子部位BMD差异有显著性(P<0.01)。随绝经年限的增加腰椎及股骨近端(NECK区、Troch区)的BMD有下降的趋势。在绝经前10年内,骨密度相对丢失较快,尤其腰椎BMD下降明显。排除了年龄和BMD的影响,对40~49岁的围绝经期妇女按是否绝经为因变量腰椎及股骨近端(NECK区、Troch区)BMD协方差分析结果:腰椎BMD(F=13.28,P=0.0004);股骨NECK区BMD(F=15.47,P=0.0001);股骨Troch区BMD(F=4.79,P=0.0305),由此可见,绝经作为一个因素在绝经期初期妇女的骨密度影响较大。结论该地区绝经期妇女随绝经年限延长,腰椎及股骨近端骨密度减低速度在绝经后10年内较快,绝经作为一个因素对中年妇女骨密度的减低有较大影响。     

脂肪因子Omentin-1、脂联素与中老年女性骨密度相关性研究

目的观察脂肪因子Omentin-1、脂联素与中老年女性骨密度之间的相关性。方法选取2017年3月至2018年4月在佛山市中医院就诊的338名女性,按照绝经状态分为围绝经期/绝经期组(n=194)和绝经后组(n=124)。将参研人员年龄、体质量指数(bone mass index,BMI)、腰围、吸烟状况、身体活动、脂联素、Omentin-1和激素进行多变量调整(ANCOVA),用于研究其脂肪因子和骨密度(bone mineral density,BMD)之间的潜在关系。结果与绝经后女性的腰椎BMD [(0. 69±0. 08)g/cm~2]相比,围绝经期女性的腰椎BMD[(0. 89±0. 09) g/cm~2]更高;在围绝经期/绝经期组女性中,脂联素和Omentin-1均与腰椎BMD无显著相关性(P0. 05);在绝经后组女性中,脂联素与腰椎BMD无相关性(P 0. 05);而在绝经后组女性中,Omentin-1与腰椎BMD呈显著负相关(P0. 05)。结论绝经后女性的Omentin-1与腰椎BMD呈负相关。     

绝经后骨质疏松症妇女血清痩素水平与骨密度的关系

目的 观察绝经后骨质疏松症妇女血清瘦素水平与骨密度(BMD)、骨矿含量(BMC)的相关性。方法 ELISA法检测32名绝经后骨质疏松症妇女(绝经组)和27名体重指数(BMI)相匹配的非绝经正常对照者(非绝经组)的空腹血清瘦素浓度,双能X线骨密度仪测定受试者腰椎BMD、BMC、T值、Z值。结果 绝经组和非绝经组的血清瘦素浓度分别为12.43±7.90ng/ml和11.76±4.42ng/ml,两组之间无差异;两组血清瘦素浓度均与体重、BMI和脂肪含量(Fat％)显著正相关,绝经组的瘦素水平与BMD及BMC无相关性,非绝经组瘦素浓度与BMDIL3和BMCL5相关(r=0.132,P<0.05;r=0.140,P<0.05),但调整BMI后瘦素浓度与BMD及BMC:的相关性消失(r=0.079,P>0.05;r=0.067,P>0.05)。结论成年妇女瘦素水平与体重、体脂及脂肪含量显著相关,瘦素不是绝经后妇女骨质疏松症的主要影响因素。     

绝经后妇女骨质疏松性椎体骨折与腰椎骨密度的关系

目的探讨绝经后妇女骨质疏松性椎体骨折与腰椎骨密度的关系。方法选择骨质疏松性椎体骨折的绝经后妇女23例为骨折组,无椎体骨折的25例绝经后骨质疏松妇女为对照组。两组的年龄、绝经年限、身高、体重、体重指数差异无显著性,均行胸腰椎正侧位X线摄片。用双能X线吸收仪（DXA）测量的腰椎（L2-4）前后位骨密度（BMD）、骨矿含量（BMC）和T值。结果骨折组BMD、BMC和T值均低于对照组（P〈0.01）。结论腰椎BMD降低与绝经后妇女的骨质疏松性椎体骨折相关。绝经后骨质疏松妇女应重视BMD变化,预防椎体骨折的发生。     

青少年强直性脊柱炎早期年龄、身高、体重、体重指数与腰椎骨量、骨密度的相关性初步分析

目的研究青少年强直性脊柱炎(Ankylosing spondylitis,AS)早期年龄、身高、体重、体重 指数(BMI)与腰椎骨矿含量(L1-4 BMC、L2-4 4BMC)、腰椎面积骨密度(L1-4 BMD、L2-4 BMD)、腰椎体积表观骨密度(L1-4 BMAD、L2-4 BMAD)之间的相关性,旨在初步探讨我国青少年AS早期骨量、骨密度的重要相关因素及评价指标.方法选择男性青少年AS早期患者31例,统计AS患者年龄(y)、身高(cm)、体重(kg)、BMI(kg/m2)、病程(mon)及ESR(mm/h)等变量,应用DPX-IQ双能X线骨密度仪(DEXA)检测L1-4BMC、L2-4 4BMC、L1-4BMD和L2-4BMD,计算L1-4BMAD和L2-4 BMAD(BMAD=BMC/面积3/2,g/cm3);采用相关和回归分析研究多因素相关性.结果年龄、身高、体重、BMI、病程、ESR、L1-4 BMC、L2-4 BMC、L1-4BMD、L2-4BMD、L1-4BMAD和L2-4BMAD的变量值分别为(17.56±2.01)y、(168.52±8.59)cm、(56.13±12.72)kg、(19.65±3.42)kg/m2、(19.61±12.39)mon、(21.71±10.04)mm/h、(52.16±12.17)g、(41.29±9.59)g、(0.971±0.139)g/cm2、(0.984±0.142)g/cm2、(0.1332±0.0146)g/m3和(0.1527±0.0173)g/m3.双因素相关分析初步证实AS早期ESR增高(51.61%AS患者ESR≥20mm/h)且与腰椎骨量、骨密度呈负相关(r=-0.509～-0.424、P=0.003～0.018).多因素回归分析表明仅体重因素进入L1-4BMD(R=-0.657,P=0.000)、L2-4BMD(R=0.620,P=0.000)、L1-4 BMAD(R=0.551,P=0.001)和L2-4BMAD(R=0.510,P=0.003)回归疗程;另一方面,身高因素成为L1-4 BMC(R=0.676,P=0.000)和L2-4BMC(R=0.673,P=0.000)主要相关因素而被纳入其回归方程.结论身高和体重即成为青少年AS早期骨量及骨密度的重要相关因素.此时期重视发挥二因素对腰椎骨矿含量和骨密度的正相关作用,将对于减缓青少年AS早期骨量丢失及AS相关性骨质疏松症有积极意义.     

绝经后女性骨质疏松合并骨折血清25羟维生素D水平研究

目的 探讨绝经后女性骨质疏松合并骨折血清25羟维生素D的水平.方法 选择2010年1月-2013年5月在解放军第309医院骨内科住院的86例患者,包括绝经后骨质疏松合并骨折患者42例,年龄(70.38±6.11)岁,不伴骨折绝经后骨质疏松患者44例,年龄(67.32±8.93)岁.采用美国Norland双光能X线骨密度检测仪对所有患者进行腰椎L2-L4和左侧股骨近端(包括Neck、Troch、Ward''s三角区)骨密度测量,并测定身高、体重、血谷丙转氨酶(ALT)、谷草转氨酶(AST)、肌酐(CRE)、尿素氮(BUN).采用酶联免疫吸附法测定两组患者血清25羟维生素D,比较两组25羟维生素D水平.结果 绝经后骨质疏松合并骨折组患者血清25羟维生素D(12.40±3.7) ng/ml,较绝经后非骨折骨质疏松患者(16.23 ±4.6)ng/ml低,差异具有统计学意义(P＜0.05);绝经后骨质疏松合并骨折组患者ALT(18.22±8.17) IU/L、AST(20.70±12.67) IU/L、CRE(56.76±11.81)umol/L、BUN(5.20±1.40) mmol/L与骨质疏松组ALT(21.32±12.16)IU/L、AST(22.16±8.36) IU/L、CRE(57.29±13.42) umol/L、BUN(5.2±1.8) mmol/L相比,差异无统计学意义(P＞0.05);绝经后骨质疏松合并骨折患者L2-4、Neck、Troch、Ward''s三角区的骨密度分别为(0.75 ±0.19) g/cm2、(0.61 ±0.18)g/cm2、(0.50±0.12) g/cm2、(0.40±0.14)g/cm2与对照组(0.81 ±0.33) g/cm2、(0.67 ±0.11)g/cm2、(0.52±0.10) g/cm2、(0.45±0.1)g/cm2相比较,差异没有统计学意义(P＞0.05).结论 绝经后骨质疏松合并骨折患者较未合并骨折骨质疏松维生素D缺乏更严重.     

绝经后2型糖尿病妇女血脂水平和骨密度的关系

目的探讨绝经后2型糖尿病妇女血脂和骨密度改变的相关性。方法将290例绝经后2型糖尿病妇女按T值分成骨质疏松组和非骨质疏松组;检测各组患者血清总胆固醇(TC)、甘油三脂(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇LDL-C)以及腰椎骨密度(BMD),然后分析血脂和骨密度的关系;对骨密度和血脂、年龄、绝经年龄等变量之间的关系进行多元逐步回归分析。结果(1)绝经后2型糖尿病妇女的HDL-C与腰椎BMD存在负相关(r=-0.305,P=0.001),LDL-C、TG、TC与腰椎BMD无相关;(2)在校正体重指数、年龄和绝经年限影响因素后,绝经后2型糖尿病妇女的HDL-C与腰椎BMD仍存在负相关(r=-0.160,P=0.018),而LDL-C、TG、TC与腰椎BMD仍无相关。(3)在多元逐步回归分析中,HDL-C(β1=-0.199,P=0.005)仍与骨密度独立相关。结论绝经后2型糖尿病妇女的HDL-C与腰椎BMD存在负相关而TC、TG、LDL-C与腰椎BMD无相关。     

辛伐他汀对绝经伴血脂代谢异常女性跟骨骨密度的影响

目的 研究辛伐他汀对绝经后伴血脂代谢异常女性跟骨骨密度的影响。方法 分析885名绝经后口服辛伐他汀治疗血脂代谢异常（TC>5.18mmol/L 或 LDL-C> 3.37mmol/L）女性的跟骨骨密度,并依据T值分为骨质正常、骨量减少、骨质疏松。结果 治疗前跟骨骨密度为305.3± 59.2 mg/cm2,骨质正常、骨量减少、骨质疏松的人数分别为115、446、324,口服辛伐他汀（20mg/d）治疗3月后骨密度为309.7±56.3 mg/cm2,骨质正常、骨量减少、骨质疏松的人数为117、459、319,12月后跟骨骨密度为312.5±60.9 mg/cm2,骨质正常、骨量减少、骨质疏松的人数为122、460、303。结论 绝经后伴血脂代谢异常女性应用辛伐他汀（20mg/d）治疗12个月后跟骨骨密度增高,但对骨质疏松患病风险无影响。     

最大限度雄激素阻断治疗前列腺癌对患者骨密度的影响

目的:探讨最大限度雄激素阻断(MAB)治疗对前列腺癌患者骨密度的影响。方法:对40例因前列腺癌行MAB治疗的患者进行调查,治疗时间7～12个月,分别于治疗前后检测血清前列腺特异性抗原(PSA)、睾酮及血钙、血磷、24 h尿钙、尿磷、碱性磷酸酶、甲状旁腺激素、血常规及肝肾功能,双能X线吸收法测定腰椎、股骨颈骨密度,并进行疼痛评分,比较MAB治疗前后各项指标差异。结果:前列腺癌患者治疗前5例(12.5%)腰椎骨量减少,8例(20.0%)腰椎骨质疏松;13例(32.5%)左股骨颈骨量减少,15例(37.5%)左股骨颈骨质疏松。MAB治疗前患者血清PSA为(52.9±69.9)μg/L,睾酮为(18.9±6.5)nmol/L,治疗后PSA为(1.5±1.6)μg/L,睾酮为(1.9±1.3)nmol/L,与治疗前比较均显著下降(P<0.05)。治疗前血钙为(2.5±0.2)mmol/L,血磷为(1.2±0.2)mmol/L,尿钙为(3.1±1.4)mmol/L,尿磷为(11.5±8.1)mmol/L,治疗后血钙为(2.5±0.1)mmol/L,血磷为(1.2±0.1)mmol/L,尿钙为(2.8±1.2)mmol/L,尿磷为(9.9±4.0)mmol/L,两者比较差异均无统计学意义(P>0.05)。治疗前后碱性磷酸酶、甲状旁腺激素、血常规、肝肾功能差异均无统计学意义(P>0.05)。治疗前腰椎和股骨颈骨密度分别为(1.1±0.1)g/cm2和(0.8±0.2)g/cm2,疼痛评分为(0.6±0.2)分,治疗后腰椎和股骨颈骨密度分别为(1.1±0.2)g/cm2和(0.8±0.1)g/cm2,疼痛评分为(0.7±0.1)分,与治疗前比较差异均无统计学意义(P>0.05)。结论:7～12个月MAB治疗对前列腺癌患者骨密度无明显影响,安全有效,但治疗前应注意监测患者骨密度。     

A comparison of radial peripheral quantitative computed tomography, calcaneal ultrasound, and axial dual energy X-ray absorptiometry measurements in women aged 45-55 yr.

Perimenopausal bone loss is considered to affect trabecular bone preferentially. Peripheral quantitative computed tomography (pQCT) quantifies trabecular bone mineral density (BMD) independently at the ultradistal radius. This article examines differences in pQCT BMD between late premenopausal and early postmenopausal women, comparing the differences with calcaneal ultrasound and axial dual energy X-ray absorptiometry measurements. One hundred nineteen normal perimenopausal women aged 45-55 yr who attended a randomized osteoporosis screening program were stratified by menopausal status into premenopausal (PRE: n = 79) and postmenopausal (POST: n = 40) groups. All measurements were lower in the postmenopausal group with the exception of ultrasonic velocity (PRE vs POST: 1397 +/- 53.8 vs 1421 +/- 58.5 m/s, p = 0.037). Total (391.8 +/- 52.9 vs 366.3 +/- 68.6 g/cm(3), p = 0.013) and subcortical (533.6 +/- 59.4 vs 504.3 +/- 79.8 g/cm(3) p = 0.018), but not trabecular (187.5 +/- 38.8 vs 173.2 +/- 46.6 g/cm(3), p = 0. 098) or cortical (561 +/- 53.4 vs 551.2 +/- 66 g/cm(3), p = 0.174), pQCT BMD measurements were significantly lower in the POST group, as were ultrasonic attenuation (79.4 +/- 16 vs 72.3 +/- 18.0 dB/Mz, p = 0.034), DXA spine (1.032 +/-16 vs 0.959 +/- 0.2 g/cm(2), p = 0.003), and all hip (p 相似文献   

Comparative effects of teriparatide and ibandronate on spine bone mineral density (BMD) and microarchitecture (TBS) in postmenopausal women with osteoporosis: a 2-year open-label study

Summary

Treatment effects over 2 years of teriparatide vs. ibandronate in postmenopausal women with osteoporosis were compared using lumbar spine bone mineral density (BMD) and trabecular bone score (TBS). Teriparatide induced larger increases in BMD and TBS compared to ibandronate, suggesting a more pronounced effect on bone microarchitecture of the bone anabolic drug.

Introduction

The trabecular bone score (TBS) is an index of bone microarchitecture, independent of bone mineral density (BMD), calculated from anteroposterior spine dual X-ray absorptiometry (DXA) scans. The potential role of TBS for monitoring treatment response with bone-active substances is not established. The aim of this study was to compare the effects of recombinant human 1–34 parathyroid hormone (teriparatide) and the bisphosphonate ibandronate (IBN), on lumbar spine (LS) BMD and TBS in postmenopausal women with osteoporosis.

Methods

Two patient groups with matched age, body mass index (BMI), and baseline LS BMD, treated with either daily subcutaneous teriparatide (N?=?65) or quarterly intravenous IBN (N?=?122) during 2 years and with available LS BMD measurements at baseline and 2 years after treatment initiation were compared.

Results

Baseline characteristics (overall mean ± SD) were similar between groups in terms of age 67.9?±?7.4 years, body mass index 23.8?±?3.8 kg/m², BMD L1–L4 0.741?±?0.100 g/cm², and TBS 1.208?±?0.100. Over 24 months, teriparatide induced a significantly larger increase in LS BMD and TBS than IBN (+7.6 %?±?6.3 vs. +2.9 %?±?3.3 and +4.3 %?±?6.6 vs. +0.3 %?±?4.1, respectively; P?<?0.0001 for both). LS BMD and TBS were only weakly correlated at baseline (r ²?=?0.04) with no correlation between the changes in BMD and TBS over 24 months.

Conclusions

In postmenopausal women with osteoporosis, a 2-year treatment with teriparatide led to a significantly larger increase in LS BMD and TBS than IBN, suggesting that teriparatide had more pronounced effects on bone microarchitecture than IBN.     

血清SM4D水平与绝经后骨质疏松症患者骨密度和骨代谢指标的相关性研究

目的探讨绝经后骨质疏松症(postmenopausal osteoporosis,POP)患者血清4D同型二聚体(SM4D)水平与骨密度(bone mineral density,BMD)和骨转换指标的关系。方法通过双能X线吸收测定法对257例POP患者和90例健康对照者进行BMD测量。通过酶联免疫吸附测定法测定受试者血清SM4D、BAP、BGP和TRACP-5b水平。使用自动电化学发光系统测量I型血清交联N端肽(NTX)、25-羟基维生素D[25(OH)D]和骨钙素的N-mid片段水平(N-MID-OT)。结果与健康对照组相比,POP妇女的SM4D水平显著升高[(1.40±0.33)μg/L vs.(0.58±0.18)μg/L,P=0.006]。SM4D水平与血清TRACP-5b和NTX水平呈正相关,与腰椎和股骨颈BMD、血清BAP和BGP水平呈负相关。SM4D水平与年龄、体质量指数以及血清25(OH)D和N-MID-OT水平之间无相关性。腰椎和股骨颈骨密度(β=-0.354,P<0.001;β=-31.234,P<0.001)和血清BAP水平(β=0.127,P=0.019)是POP患者血清SM4D水平的独立预测因子。结论绝经后骨质疏松症女性SM4D与骨密度和骨转换指标密切相关。     

Evaluation of bone mineral density in postmenopausal women in Kuwait

Menopause is the major risk factor for the loss of bone mineral density (BMD) and bone mineral content (BMC) in women. In this study, we determined the prevalence of osteoporosis in postmenopausal women in Kuwait and compared it with that of other Middle East and west countries. Two thousand two hundred ninety-six postmenopausal women ranging in age from 40 to 87yr were included in the study and divided into 4 age groups by decade. We measured body weight, height, body mass index (BMI), BMD, and BMC. The mean age, height, and weight were 59.1+7.9yr, 154.7+6.5cm, and 77.3+14.9kg, respectively. The mean BMI and BMC were 32.4+6.6kg/m(2) and 0.9+0.14g/cm(2), respectively. The average T-scores for the hip and lumbar spine were -0.280+1.2 and -1.297+1.33, respectively. BMC significantly decreased with age from 0.95 to 0.81g/cm(2). Four hundred forty-four (19.3%) were found to have osteoporosis. The incidence of osteoporosis significantly increased from 4.3% to 39.9% with age, which is lower than that reported for Saudi (40%) and Moroccan women (39.6%) and higher than that for US/European (31%) and Lebanese women (11%).     

Use of a Swedish T-score reference population for women causes a two-fold increase in the amount of postmenopausal Swedish patients that fulfill the WHO criteria for osteoporosis

The WHO criteria for osteoporosis are based on bone mineral density (BMD) values in comparison to a reference population of healthy young adults. The aim of this study was to create BMD references for ethnic Swedish women, and to investigate whether the use of these T-score measurements influence the amount of Swedish postmenopausal patients that are diagnosed as having osteoporosis. A bone density reference was created by measuring a population-based sample of 335 randomly selected Swedish women aged 20-39yr. BMD was measured by dual-energy X-ray absorptiometry (DXA) at the lumbar spine, proximal femur, and total body. These locally derived T-score values were subsequently used to diagnose a sample of 300 consecutive postmenopausal Swedish patients referred to the Uppsala Osteoporosis Unit. There was a slight age-dependent decrease in femoral neck BMD, whereas no age effect was seen at other sites such as total hip, lumbar spine, or total body. This suggests that the cohort represents the steady state BMD at the ages of expected peak bone mass in Swedish women. The correlation between BMD measures at different sites differed from r=0.55 (lumbar spine BMD vs femoral neck BMD [FNBMD]) to r=0.92 (total hip BMD vs FNBMD). Central DXA-generated T-scores were calculated from this cohort, and these were significantly higher (0.3-0.5 SD) as compared with manufacturers and NHANESIII reference populations. This indicates that young Swedish women have a higher peak bone mass than the subjects included in the reference populations currently used for clinical measurements. The T-score in total hip derived from the investigated cohort was subsequently used to diagnose 300 clinical patients (mean age 63yr) referred for a DXA scan by their physicians. The use of this locally established and ethnic representative, T-score reference increased the prevalence of osteoporosis in femoral neck and total hip with 53-106%. A Swedish female BMD reference representing peak bone mass has been established and the normative data are presented. Notably, this cohort has considerably higher BMD as compared to the NHANESIII and manufacturer's reference populations. The use of the present T-score reference therefore causes approximately a 2-fold increase in the amount of Swedish postmenopausal women that fulfill the WHO criteria for osteoporosis. This demonstrates the problems with using T-score as diagnostic threshold for osteoporosis and is an argument for future strategies to obtain standardized densitometric cut-offs, for example, mg/cm(2).     

Association Among Age, Height, Weight, and Body Mass Index with Discordant Regional Bone Mineral Density

Patients with osteoporosis have a body mass index (BMI) that is significantly lower than patients with normal bone mineral density (BMD). This study was conducted to examine the associations among age, height, weight, and BMI in patients with discordant regional BMD. For the purpose of this study, discordant regional BMD was defined as having a BMD result that is in the osteoporotic range at one site while being normal at the other sites. Data from 7513 qualifying bone densitometry scans from a suburban Detroit osteoporosis testing center were analyzed. A patient was classified as having generalized osteoporosis if the T-score was < 2.5 at the lumbar spine, femoral neck, and distal radius and normal if the T-score was > 1 at the same three sites. Patients were determined to have discordant low BMD when the T-score was < 2.5 at one site while the T-score was > 1 at the other two sites. Patients with generalized osteoporosis were older (mean age: 72.2 vs 54.7 yr; p < 0.001), shorter (height: 153.1 vs 161.7 cm; p < 0.001) and had lower BMI (23.7 vs 28.5 kg/m(2); p < 0.001) compared with patients with normal BMD. The distal radius was the site where discordant osteoporosis was most prevalent (70 patients, 0.9%). Patients with isolated low distal radius BMD were similar in age (mean age: 70.4 vs 72.2. yr; p = NS), but were taller (height: 158.6 vs 153.1 cm; p < 0.001) and had BMI values that were significantly higher (BMI: 28.7 vs 23.7 kg/m(2); p < 0.001) than patients with generalized osteoporosis. Patients with discordant BMD at the distal radius had anthropometric characteristics that were significantly different from patients with generalized osteoporosis. These differences may represent differences in the etiology of osteoporosis and differential effects on cortical vs trabecular bone.